- Comparison of the Efficacy of Octreotide Long-acting Repeatable and Lanreotide Autogel in Acromegalic Patients.
-
Seul young Kim, Dohee Kim
-
J Korean Endocr Soc. 2010;25(1):37-45. Published online March 1, 2010
-
DOI: https://doi.org/10.3803/jkes.2010.25.1.37
-
-
1,896
View
-
26
Download
-
1
Crossref
-
 Abstract
 PDF
- BACKGROUND
Somatostatin analogues have been used as the first-line medical therapy for active acromegaly that is not completely cured, or which recurs after surgery. The aim of this study was to compare the effects of octreotide long-acting repeatable (LAR) and lanreotide Autogel. Such a comparison has not been reported in Korea. METHODS: Twenty-seven patients who had previously undergone surgery for acromegaly from December 2003 to March 2005 were included. We retrospectively investigated eight patients who underwent operation only and 19 patients who additionally received medical treatment after surgery (octreotide LAR, n = 5; lanreotide Autogel, n = 5). Growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels were measured. RESULTS: The mean pre-operative and post-operative levels of GH were lower in patients who underwent surgery only than in those who received adjuvant therapy, but IGF-I levels were not significantly different. In the 19 patients receiving medical treatment after unsuccessful surgery, the mean baseline GH levels were 24.2 microgram/L for octreotide LAR and 22.8 microgram/L for lanreotide Autogel (P = 0.711), and the mean GH levels 36 months post-treatment were 4.1 microgram/L and 2.5 microgram/L, respectively (P = 0.794). GH < 2.5 microgram/L represented 30% of octreotide LAR patients and 33.3% of lanreotide Autogel patients (P = 0.91). Patients with normal IGF-I levels represented 54.5% and 66.7%, respectively (P = 0.71). CONCLUSION: No significant difference in therapeutic effect of octreotide LAR and lanreotide Autogel was evident in 19 Korean acromegalic patients who were not completely cured by surgery and radiation therapy.
-
Citations
Citations to this article as recorded by  - Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
Sang Ouk Chin, Cheol Ryong Ku, Byung Joon Kim, Sung-Woon Kim, Kyeong Hye Park, Kee Ho Song, Seungjoon Oh, Hyun Koo Yoon, Eun Jig Lee, Jung Min Lee, Jung Soo Lim, Jung Hee Kim, Kwang Joon Kim, Heung Yong Jin, Dae Jung Kim, Kyung Ae Lee, Seong-Su Moon, Dong
Endocrinology and Metabolism.2019; 34(1): 53. CrossRef
- The Relationship between the Expression of MHC Class II Antigens and the Clinical Prognosis of Papillary Thyroid Carcinoma Patients.
-
Jun Chul Lee, Seul Young Kim, Yun Sun Choi, Youn Sun Bai, Yun Jeung Kim, Ihn Suk Lee, Ki Hyun Kwon, So Young Rha, Bon Jeong Ku, Young Kun Kim, Heung Kyu Ro, Shengjin Li, Jin Man Kim, Young Suk Jo, Minho Shong
-
J Korean Endocr Soc. 2007;22(1):26-34. Published online February 1, 2007
-
DOI: https://doi.org/10.3803/jkes.2007.22.1.26
-
-
Abstract
PDF
- BACKGROUND
Papillary thyroid carcinoma is among the most curable cancers, but some patients are at high risk for recurrence or even death. MHC antigens are essential molecules for the pathogenesis of carcinoma and also the physiologic immune responses against tumor. However, there is no data about the relationship between the expression of MHC antigens and the clinical prognosis of papillary thyroid carcinoma patients. METHODS: We analyzed the relationship between the various prognostic factors and the MHC antigen expression by conducting a retrospective study of 215 patients, who had undergone thyroidectomy for papillary thyroid carcinoma between 1987 and 2003. RESULTS: The expressions of MHC class II antigens were more frequent in papillary thyroid carcinoma than in the other thyroid diseases. Yet there was no statistically significant relationship between most of the clinicopathological factors and the expression of MHC class II antigens in papillary thyroid carcinoma patients. Interestingly, an HLA-DR expression was found in 8 (30.8%) of the 26 patients in the recurrence group and in 13 (76.5%) of the 17 patients in the non-recurrence group, and HLA-DP/DQ immunoreactivity was positive in 10 (38.5%) cases of the recurrence group and in 14 (82.4%) cases of the non-recurrence group. CONCLUSION: Papillary thyroid carcinoma showed a more frequent expression of MHC Class II antigens. However, the recurred papillary thyroid carcinoma showed a tendency to downregulate the expression of MHC class II antigens. Hence, the molecular mechanism for the expression of MHC class II antigens might have a role in the recurrence of papillary thyroid carcinoma.
|
KES
